Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 4/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | CALCA | P06881 | 5/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | TEC | P42680 | 1/20 | 0.31 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657714 | 0.91 | CYP3A4 (0.42) | CYP3A4ACACBCALCACALCRL | |
| SCHEMBL5659279 | 0.91 | CYP3A4 (0.42) | CYP3A4ACACBCALCACALCRL | |
| SCHEMBL5660254 | 0.87 | CYP3A4 (0.36) | CYP3A4BTKROCK2CALCACALCRL | |
| SCHEMBL5658453 | 0.87 | CALCA (0.33) | CYP3A4BTKROCK2CALCACALCRL | |
| SCHEMBL5657726 | 0.85 | RXRA (0.40) | CYP3A4ACACBBTKROCK2CALCA | |
| SCHEMBL5656758 | 0.84 | BTK (0.32) | CYP3A4BTKROCK2 | |
| SCHEMBL5659437 | 0.82 | BTK (0.36) | CYP3A4BTKROCK2JAK3CALCRL | |
| SCHEMBL4862072 | 0.81 | ACACB (0.38) | ACACBCALCA | |
| SCHEMBL5660671 | 0.81 | ROCK2 (0.44) | CYP3A4ROCK2 | |
| SCHEMBL5661661 | 0.80 | CALCA (0.47) | CALCACALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| US-7205294-B2 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-17 | — | — | US | disclosed |
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BDKRB1, BDKRB2, CALCRL | CYP3A4 1053/4885ACACB 4648/4885BTK 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.